Roche annual profit disappoints, outlook muted

Cancer drug maker Roche (ROG.VX) followed Swiss rival Novartis (NOVN.VX) in unsatisfying shareholders with a muted forecast for the year, causing its shares lower on Thursday.

Analysts voiced issues that Roche's 3 huge cancer treatments -- Herceptin, Rituxan and Avastin -- can be facing slower growth even before the primary emulator medicine aiming for a share of their revenue proceed the market in 2017.

Roche incomprehensible  analysts' sales and profit forecasts for 2015. It currently expects revenue to rise at a "low-to-mid-single digit share rate" this year and core earnings per share would expand quicker than sales at constant exchange rates.

On Wednesday, Novartis forecast solely stagnant results for this year. The Roche forecast of slow growth didn't impress investors and shares fell four % by 1230 GMT (7:30 a.m. ET).

The outlook is additional muted than Roche's final forecast for 2015, though Chief govt Severin Schwan saw scope for things to show out higher.

"We don't need to vow an excessive amount of -- we'd rather surpass expectations than do the other," Schwan aforesaid in associate interview.

"I suppose it is a solid outlook. we would like to spice up growth once more and increase profitableness at constant time."

One analyst aforesaid the steering understood flat 2016 earnings, well below market agreement, once the impact of exchange rates was factored in.

NEW MEDICINES

Other analysts targeted on the outlook for Herceptin, Rituxan and Avastin that account for higher than half drug sales.

"Sales growth in our opinion might lose momentum in 2016, as a result of Roche's 3 main product area unit moving inexorably toward a highland, even while not the arrival of biosimilars," wrote archangel Nawrath, a Zuercher Kantonalbank analyst.

He side that the dividend hike to eight.10 francs per share incomprehensible  expectations for additional, too.

For 2015, Roche denote core lucre of eleven.84 billion Swiss francs ($11.64 billion), compared to a Reuters poll for twelve.2 billion francs.

Sales rose one % to forty eight.145 billion francs in 2015, compared to analyst forecasts of forty eight.4 billion francs. In constant currencies, sales rose five %.

Schwan, a noticeable talking Austrian professional and social scientist by coaching, is hoping on new therapy treatments for cancer furthermore as medications for disseminated sclerosis to offset patent expiries that may leave Roche prone to biosimilar copycats in 2 years.

"We currently expect to launch up to eight new medicines over consequent 3 years, that is really associate new range for Roche," Schwan aforesaid.